Objectives To assess the prognostic value of human epididymis protein 4 (HE4) kinetics
during and after neoadjuvant chemotherapy (NACT) cycles compared with cancer antigen …

Abstract Human epididymis protein 4 (HE4) is a novel tumour marker in epithelial ovarian
cancer (EOC). Data on its profile and predictive potential for subsequent outcome after …

Objective Human epididymis protein 4 (HE4) is a validated, complementary biomarker to
cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently …

Background Ovarian cancer (OC) is considered the most lethal gynecological cancer, of
which more than 65% cases are diagnosed in advanced stages, requiring platinum-based …

Objective Human epididymis protein 4 (HE4) is a promising novel serum biomarker for the
detection of early-stage epithelial ovarian cancer (EOC) and for the differential diagnosis …

Abstract Introduction: Epithelial Ovarian Cancer, tubal-and peritoneal cancer (EOC) is still
the major cause of death in gynecological cancer. The outcome of primary surgery is an …

Epithelial ovarian cancer (EOC) remains the deadliest form of gynecological cancers.
Optimal tumor debulking, no matter the primary or the interval, is the most important …

OBJECTIVES: Epithelial ovarian cancer (EOC) is the major cause of death due to
gynecological malignancies. The most important prognostic factors are residual tumor mass …

Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human
epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim …

Clinical utility of new biomarkers often requires the identification of their optimal threshold.
This external validation study was conducted to assess the performance of the preoperative …